MTN 035 (DESIRE)
Status:Ongoing
Phase:Open Label
Principal Investigator(s):
Objective:MTN-035, or DESIRE (Developing and Evaluating Short-acting Innovations for Rectal Use), is an open label crossover study to systematically examine three methods for delivering drugs to help prevent HIV infection from anal sex.
Last updated May 9, 2021
Prevention Option(s):Microbicides
Study Design:Double-blind, Randomized
Official Code:
NCT03671239
Trial Sponsors:
NIAID (DAIDS-ES: 38459)
Start Date
End Date
April 9, 2019
July 8, 2020
Enrollment:217
Age range:
18 Years ↔
35
Population:Cisgender Men, Transgender Men, Transgender Women